How an open platform can shake up the drug development process

TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

By Kim Ribbink • April 28, 2022

Laura Randa's aim to break down mental healthcare barriers for disabled patients

Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.

By Alexandra Pecci • April 27, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan

As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.

By Taren Grom • April 27, 2022

Real-world data is making drug development more true to life

How RWD is moving from the background to the spotlight in pharma’s development process.

By Kelly Bilodeau • April 26, 2022

Mouse vs. machine: Using AI to solve the animal testing model in pharma

Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

By Michael Gibney • April 26, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022

Dispelling the 5 myths of biopharma brand planning

Many biopharma marketers have worked for more than one company during their career. 

April 25, 2022

From the fringes to the forefront — the mRNA era has taken hold of pharma

A look at what’s next for the industry’s buzziest technology.

By Kim Ribbink • April 22, 2022

A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

By Alexandra Pecci • April 21, 2022

The cannabis vanguard: A rare disease company looks to pioneer in the space

Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

By Jared Whitlock • April 21, 2022

For Global Blood Therapeutics, the connection to sickle cell disease runs deep

An underserved patient population is a guiding light for the company, which recently scored a new approval.

By Robin Robinson • April 19, 2022

A pharma mystery: Cancer-causing impurities drive joint search for answers

Pharmaceutical industry insiders and regulators are striving to overcome the ‘blind spots’ that contribute to nitrosamine contamination.

By Michael Gibney • April 19, 2022

How pharma can up its social media game

Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

By Karissa Waddick • April 18, 2022

Clinical content that meets the top 3 needs of HCPs

Learn how to meet the needs of HCPs with clinical content designed to be served up, save time, and satisfy curiosity.

By Rob Spalding is the Chief Strategy & Marketing Officer at Avant Healthcare • April 18, 2022

With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

What now? Alzheimer's drugmakers ponder the path to approval

Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

By Kelly Bilodeau • April 14, 2022

Woman of the Week: iSpecimen's Jill Mullan

Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

By Taren Grom • April 13, 2022

Biotech goes Hollywood

A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

By Taren Grom • April 13, 2022

'Bootcamp' helps rare disease advocates learn the ropes of drug development

Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

By Kim Ribbink • April 12, 2022

Why the war in Ukraine could accelerate the deglobalization of clinical trials

COVID-19 slowed many studies — but the war could further strain clinical trials worldwide.

By Michael Gibney • April 12, 2022

How Congress could play a role in personalized medicine

PGx — a tool to help determine proper dosing — may be poised to achieve broader use in healthcare and pharma.

By Kelly Bilodeau • April 11, 2022

Optinose CEO senses big opportunities for the company's nasal delivery device

Peter Miller explains how a repackaged sinus drug has won late-stage clinical success.

By Jared Whitlock • April 11, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

A planned trial revives a glimmer of hope for a Huntington's disease treatment

Roche brought a Huntington’s drug back to life after a jarring trial halt.

By Kelly Bilodeau • April 6, 2022

Seeing yourself at the top: Alnylam CEO on why representation matters

Dr. Yvonne Greenstreet became just the sixth woman in the world to head up a biopharma company with a market cap of more than $5 billion when she took on the role of CEO in January.

By Alexandra Pecci • April 6, 2022